Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|March 2, 2014
- Pharmaceutical Technology-03-02-2014
- Volume 38
- Issue 3
7900 ICP-MS Increases Efficiency
7900 ICP-MS Increases Efficiency
The 7900 ICP-MS from Agilent Technolgies is a redesign of the 7700 Series. The instruments high-matrix technology allows laboratories to measure samples containing up to 25% total dissolved solids. This is 10 times higher than the current benchmark held by the 7700 ICP-MS, according to the company. The 7900’s new interface design, expansion-stage vacuum system, and orthogonal detector system (ODS) reduce background and improve sensitivity, improving signal to noise for 10-fold lower detection limits, according to the company. The patented ODS technology delivers up to 11 orders of magnitude dynamic range, from sub-ppt to percent-level concentrations, which enables users to measure trace elements and majors in the same run. In addition, the redesigned MassHunter software features a simpler user interface along with increased method automation capabilities.
Articles in this issue
over 12 years ago
Under New Ownershipover 12 years ago
Current issues with nanomedicinesover 12 years ago
Optimizing Solid Dosage Manufacturingover 12 years ago
European Union Packaging Safety Features Come into Effectover 12 years ago
Comparing Drug Layering and Direct Pelletization Processesover 12 years ago
Regulators Get Tough on Corruption in Chinaover 12 years ago
Best Practices in Adopting Single-Use Systemsover 12 years ago
Manufacturers Struggle with Breakthrough Drug Developmentover 12 years ago
Trends and Best Practices in Visual InspectionRelated to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.